- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00666562
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer
A Phase II Randomized, Placebo-Controlled Trial of Polyphenon E to Evaluate Bladder Tissue Levels of EGCG
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES I. To compare the levels of epigallocatechin-3-gallate (EGCG) in nonmalignant bladder tissue from patients with bladder cancer treated with oral polyphenon E 800 mg EGCG or polyphenon E 1200 mg EGCG once daily for 14-28 days.
SECONDARY OBJECTIVES:
I. To compare the levels of EGCG in nonmalignant versus malignant bladder tissue samples from these patients.
II. To examine the dose-response modulation of surrogate intermediate endpoint biomarkers (e.g., Proliferating Cell Nuclear Antigen [PCNA], Matrix Metallopeptidase 2 [MMP2], clusterin, Vascular endothelial Growth Factor [VEGF], p27, and ODC) in malignant and nonmalignant samples of bladder tissue from these patients after administration of polyphenon E.
III. To correlate EGCG levels in samples of serum, urine, and tissue from these patients.
IV. To examine the levels of other catechins (i.e., epicatechin, epicatechin gallate, and epigallocatechin) found in polyphenon E in samples of serum, urine, and tissue from these patients.
V. To compare the metabolism of EGCG by Catechol-O-Methyltransferase (COMT) and Uridinediphosphate-Glucuronosyltransferase (UGT) in relation to pharmacogenetic polymorphisms in COMT and UGT in samples of serum, urine, and tissue from these patients.
VI. To examine the changes in serum Insulin Growth Factor 1 (IGF-1) and IGFBP-3 levels after administration of polyphenon E in these patients.
OUTLINE:
This is a multicenter study. Patients are stratified according to tumor site and disease invasiveness (invasive vs noninvasive). Patients are randomized to 1 of 3 treatment arms.
Arm I: Patients receive six oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
Arm II: Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
Arm III: Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity.
After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
Blood, urine, and tissue samples are obtained at baseline and at the end of study treatment for correlative laboratory studies. Samples are evaluated for pharmacokinetics of polyphenon E using high performance liquid chromatography. Levels of epigallocatechin-3-gallate [EGCG] and other catechins found in polyphenon E are assessed for correlation in serum, urine, and tissue. Intermediate endpoint biomarkers are evaluated for dose-response modulation in serum (i.e., IGF-1 and IGFBP-3) via ELISA and in bladder tissue obtained at the time of bladder surgery (i.e., PCNA, MMP2, clusterin, VEGF, p27, and ODS) via IHC. Patients at the University of Wisconsin undergo additional biopsy of bladder tissue for matrix-assisted laser desorption quadrupole time-of-flight (O-MALDI-qTOF) analysis of EGCG pharmacokinetics. Tissue samples are examined for intracellular concentration and distribution of EGCG. Genotyping studies for pyrosequencing of UGT and COMT polymorphisms are also performed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Massachusetts
-
Burlington, Massachusetts, United States, 01805
- Lahey Hospital and Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55417
- Minneapolis Veterans Medical Center
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Urology San Antonio Research PA
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Hospital and Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Criteria:
- Diagnosis of bladder cancer
- Bladder tumor discovered on cystoscopy within the past 60 days
- Invasive or non-invasive tumor
- Primary tumor may represent either an initial diagnosis or recurrent disease of any clinical stage
- No metastatic disease
- Must be an eligible candidate for a partial cystectomy, radical cystectomy, or trans-urethral resection of bladder tumor (TURBT)
- Has not undergone any treatment for superficial or invasive bladder cancer since the diagnostic cystoscopy
- TURBT or radical cystectomy is the planned curative surgical treatment
- ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%
- More than 30 days since any prior intravesical therapy or adjuvant chemotherapy
- More than 30 days since prior bladder surgery
- Biopsies are not considered surgeries
- No prior pelvic radiotherapy
- No concurrent systemic chemotherapy for any other cancer, except nonmelanoma skin cancer
- No concurrent NSAIDs (e.g., ibuprofen, naproxen, or cyclooxygenase-2 inhibitors) except =< 81 mg aspirin per day
- Concurrent acetaminophen (Tylenol) or prescription opioids combined with acetaminophen (i.e., Percocet, Darvocet, Vicodin, Tylenol #3) allowed for pain
- No other concurrent investigational agents
- White Blood Cell (WBC) >= 3,000/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin >= 10 g/dL
- Alkaline phosphatase =< upper limit of normal (ULN)
- Bilirubin =< ULN
- Asparate Aminotransferase (AST) and Alanine Transaminase (ALT) =< ULN
- Sodium 135-144 mmol/L (inclusive)
- Potassium 3.2-4.8 mmol/L (inclusive)
- Chloride 85-114 mmol/L (inclusive)
- Bicarbonate >11 mEQ/dL
- Negative pregnancy test
- Fertile patients must use effective contraception
- Willing to avoid green tea beverages and green tea-containing products during study participation
- No evidence of other cancers, except nonmelanoma skin cancer
- No history of allergic reactions attributed to tea or to any of the compounds of similar chemical or biologic composition to Polyphenon E or any of the inactive ingredients in Polyphenon E capsules
- No uncontrolled intercurrent illness including, but not limited to, any of the following: Ongoing or active infection, Symptomatic congestive heart failure, Unstable angina pectoris, Cardiac arrhythmia, Psychiatric illness/social situations that would limit study compliance
- More than 24 hours since prior and no concurrent consumption of any other green tea supplements or more than 2 cups (16 oz) of green tea either through dietary sources or through nutritional supplementation
- Topical cosmetics (i.e., lotions, shampoos, makeup) that contain green tea are allowed
- Creatinine normal
- Not pregnant or nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Arm I (placebo)
Patients receive six oral placebo capsules once daily for 14-28 days.
|
Correlative studies
Correlative studies
Given orally
Other Names:
|
Experimental: Arm II (polyphenon E, placebo)
Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
|
Correlative studies
Correlative studies
Given orally
Other Names:
Given orally
Other Names:
|
Experimental: Arm III (polyphenon E, trans-urethral resection or cystectomy)
Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity.
After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
|
Correlative studies
Correlative studies
Undergo surgery
Given orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epigallocatechin Gallate (EGCG) Levels in Nonmalignant Bladder Tissue (e.g., Normal-appearing Urothelium, Inflammatory Lesions in the Bladder, Sessile Noninvasive Bladder Tumors, and Papillary Noninvasive Bladder Tumors)
Time Frame: up to 28 days
|
Comparison of nonmalignant bladder tissue levels of EGCG between the placebo group and the EGCG groups combined using student t-test.
|
up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of EGCG in Malignant Bladder Tissue
Time Frame: up to 28 days
|
up to 28 days
|
|
Levels of Surrogate Intermediate Endpoint Biomarkers in Malignant and Nonmalignant Bladder Tissue Assessed by Immunohistochemistry
Time Frame: up to 28 days
|
up to 28 days
|
|
Serum Insulin Growth Factor-1 (IGF-1) Levels Assessed by ELISA
Time Frame: Baseline and up to day 28
|
Baseline and up to day 28
|
|
Levels of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Tumor Tissue Samples
Time Frame: up to 28 days
|
up to 28 days
|
|
Absolute Change for Baseline From EGCG in Serum Samples
Time Frame: Baseline and up to 28 days
|
The difference between the amount at the end of study (up to 28 days) from baseline.
|
Baseline and up to 28 days
|
Metabolism of EGCG in Serum and Urine in Relation to Pharmacogenetic Polymorphisms in Catechol-O-Methyltransferase (COMT)
Time Frame: At Baseline
|
At Baseline
|
|
Serum IGFBP-3 Levels Assessed by ELISA
Time Frame: Baseline and up to 28 days
|
Baseline and up to 28 days
|
|
Levels of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Normal Tissue Samples
Time Frame: up to 28 days
|
up to 28 days
|
|
Absolute Change From Baseline of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E in Urine Samples
Time Frame: Baseline and up to 28 days
|
The difference between the amount at the end of study (up to 28 days) from baseline.
|
Baseline and up to 28 days
|
Absolute Change From Baseline of Other Catechins (Epicatechin Gallate, Epicatechin, and Epigallocatechin) Found in Polyphenon E Plasma Samples
Time Frame: Baseline and up to 28 days
|
The difference between the amount at the end of study (up to 28 days) from baseline.
|
Baseline and up to 28 days
|
Absolute Change for Baseline of EGCG in Urine Samples
Time Frame: Baseline and up to 28 days
|
The difference between the amount at the end of study (up to 28 days) from baseline.
|
Baseline and up to 28 days
|
Metabolism of EGCG in Serum and Urine in Relation to Pharmacogenetic Polymorphisms in Uridinediphosphate- Glucuronosyltransferase (UGT)
Time Frame: At Baseline
|
At Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tracy Downs, University of Wisconsin, Madison
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Urinary Bladder Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Neuroprotective Agents
- Protective Agents
- Antioxidants
- Anticarcinogenic Agents
- Antimutagenic Agents
- Epigallocatechin gallate
Other Study ID Numbers
- NCI-2009-00906 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA014520 (U.S. NIH Grant/Contract)
- N01CN35153 (U.S. NIH Grant/Contract)
- CO06810
- CDR0000594276
- H-2007-0250
- UWI06-8-01 (Other Identifier: DCP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage III Bladder Cancer
-
Mayo ClinicNational Cancer Institute (NCI)CompletedStage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder CancerCanada, United States, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8United States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Renal Cell Cancer | Recurrent Bladder Carcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Infiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupCompletedBladder Urothelial Carcinoma | Stage I Bladder Cancer AJCC v6 and v7 | Stage II Bladder Cancer AJCC v6 and v7 | Stage III Bladder Cancer AJCC v6 and v7United States, Canada
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States